Bryce Alexander1, Sohaib Haseeb1, Henri van Rooy2, Gary Tse3, Wilma Hopman1, Manuel Martinez-Selles2, Antoni Bayés de Luna4, Göksel Çinier5, Adrian Baranchuk1. 1. Division of Cardiology, Queen's University, Kingston, Ontario, Canada. 2. Servicio de Cardiología, Hospital Universitario Gregorio Marañón, CIBERCV, Universidad Europea, Universidad Complutense, Madrid, Spain. 3. Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, New Territories, Hong Kong. 4. Institut Català Ciències Cardiovasculars (ICCC). Hospital de la Santa Creu i de Sant Pau. Barcelona. Spain. 5. Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center Department of Cardiology, Kadikoy, Istanbul, Turkey.
Abstract
BACKGROUND: Reduced P-wave voltage in lead 1 (PVL1) has been associated with atrial fibrillation (AF) recurrence.This study sought to determine the association between reduced PVL1 and AF in the NSTEMI population and the correlation between reduced PVL1 and interatrial block (IAB)/coronary artery disease (CAD). METHODS: Data were recorded for clinical, echocardiographic, angiographic, electrocardiographic and outcome variables. Patients were followed for a minimum of one year. Chi-square tests, independent samples t-tests and one-way ANOVA were used for the analysis, which was done using IBM SPSS Results: : A total of 322 consecutive patients were included in the analysis. Patients with new-onset AF had a significantly lower PVL1 (0.085 ± 0.030mV vs. 0.103 ± 0.037mV; p=0.007). There was a significant difference in mean PVL1 between those with no IAB, partial IAB and advanced IAB (p = <0.001). Those with any type of IAB had a significantly lower mean PVL1 than those without (0.094 ± 0.032 mV vs. 0.106 ± 0.038 mV; p=0.005). Patients who developed AF had a significantly longer P-wave duration (126 ± 20ms vs. 119 ± 17ms; p=0.022). Patients with IAB were more likely to develop new-onset AF (15.4% versus 7.5%, p=0.025). There were significant co-linear associations between reduced PVL1 and IAB (p=0.005); reduced PVL1 and diffuse CAD (p=0.031) and IAB and diffuse CAD (p=0.022).
BACKGROUND: Reduced P-wave voltage in lead 1 (PVL1) has been associated with atrial fibrillation (AF) recurrence.This study sought to determine the association between reduced PVL1 and AF in the NSTEMI population and the correlation between reduced PVL1 and interatrial block (IAB)/coronary artery disease (CAD). METHODS: Data were recorded for clinical, echocardiographic, angiographic, electrocardiographic and outcome variables. Patients were followed for a minimum of one year. Chi-square tests, independent samples t-tests and one-way ANOVA were used for the analysis, which was done using IBM SPSS Results: : A total of 322 consecutive patients were included in the analysis. Patients with new-onset AF had a significantly lower PVL1 (0.085 ± 0.030mV vs. 0.103 ± 0.037mV; p=0.007). There was a significant difference in mean PVL1 between those with no IAB, partial IAB and advanced IAB (p = <0.001). Those with any type of IAB had a significantly lower mean PVL1 than those without (0.094 ± 0.032 mV vs. 0.106 ± 0.038 mV; p=0.005). Patients who developed AF had a significantly longer P-wave duration (126 ± 20ms vs. 119 ± 17ms; p=0.022). Patients with IAB were more likely to develop new-onset AF (15.4% versus 7.5%, p=0.025). There were significant co-linear associations between reduced PVL1 and IAB (p=0.005); reduced PVL1 and diffuse CAD (p=0.031) and IAB and diffuse CAD (p=0.022).
Authors: Fariha Sadiq Ali; Andres Enriquez; Diego Conde; Damian Redfearn; Kevin Michael; Christopher Simpson; Hoshiar Abdollah; Antoni Bayés de Luna; Wilma Hopman; Adrian Baranchuk Journal: Ann Noninvasive Electrocardiol Date: 2015-02-02 Impact factor: 1.468
Authors: Enes E Gul; Raveen Pal; Jane Caldwell; Usama Boles; Wilma Hopman; Benedict Glover; Kevin A Michael; Damian Redfearn; Chris Simpson; Hoshiar Abdollah; Adrian Baranchuk Journal: Ann Noninvasive Electrocardiol Date: 2016-12-25 Impact factor: 1.468
Authors: Stefan H Hohnloser; Alessandro Capucci; Eric Fain; Michael R Gold; Isabelle C van Gelder; Jeff Healey; Carsten W Israel; Chu P Lau; Carlos Morillo; Stuart J Connolly Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Sanne de Jong; Toon A B van Veen; Harold V M van Rijen; Jacques M T de Bakker Journal: J Cardiovasc Pharmacol Date: 2011-06 Impact factor: 3.105
Authors: Andres Enriquez; Axel Sarrias; Roger Villuendas; Fariha Sadiq Ali; Diego Conde; Wilma M Hopman; Damian P Redfearn; Kevin Michael; Christopher Simpson; Antoni Bayés De Luna; Antoni Bayés-Genís; Adrian Baranchuk Journal: Europace Date: 2015-02-10 Impact factor: 5.214
Authors: Eva M Benito; Alicia Carlosena-Remirez; Eduard Guasch; Susana Prat-González; Rosario J Perea; Rosa Figueras; Roger Borràs; David Andreu; Elena Arbelo; J Maria Tolosana; Felipe Bisbal; Josep Brugada; Antonio Berruezo; Lluis Mont Journal: Europace Date: 2017-08-01 Impact factor: 5.214
Authors: Bryce Alexander; Julia Milden; Bachar Hazim; Sohaib Haseeb; Antoni Bayes-Genis; Roberto Elosua; Manuel Martínez-Sellés; Cynthia Yeung; Wilma Hopman; Antoni Bayes de Luna; Adrian Baranchuk Journal: Ann Noninvasive Electrocardiol Date: 2019-06-11 Impact factor: 1.468
Authors: Mengqi Gong; Angel Cheung; Qun-Shan Wang; Guangping Li; Christos A Goudis; George Bazoukis; Gregory Y H Lip; Adrian Baranchuk; Panagiotis Korantzopoulos; Konstantinos P Letsas; Gary Tse; Tong Liu Journal: J Clin Lab Anal Date: 2020-01-09 Impact factor: 2.352